Extended Data Fig. 9: In vivo potency trial endpoints of Med411FH PDXs treated with EPHA2 CAR T cells. | Nature Medicine

Extended Data Fig. 9: In vivo potency trial endpoints of Med411FH PDXs treated with EPHA2 CAR T cells.

From: Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma

Extended Data Fig. 9

Bioluminescence (BLI) and endpoint Hematoxylin-eosin (H&E) staining analysis of NSG mice xenografted with luciferase-expressing Med411FH, infused a, via the lateral ventricle or b, IV with EPHA2 CAR T cells at dose range of 2.5×106, 5.0×106 and 10×106 as indicated (colour map for all images indicates radiance, min = 5×104, max = 5×106). Each column represents one mouse, each row represents the indicated time point and subsequent final BLI. Results representative of 2 independent replicates. c, Measurement of tumour burden over time expressed as Total Flux (photons/s) following one round of lateral ventricle versus IV EPHA2 CAR T cell therapy. ***P < 0.0005, **P < 0.005, *P < 0.05, by ANOVA followed by Tukey post hoc test, n = 3 EPHA2 CAR T cells delivered intrathecally, n = 3 EPHA2 CARs T cells delivered IV for each dose range, centre lines show the mean ± SEM performed in triplicate. Infusion of 2.5×106 EPHA2: Day 0 IV vs LV P = 0.7, Day 30 IV vs LV P = 0.0004; 5.0×106 EPHA2: Day 0 IV vs LV P = 0.03, Day 30 IV vs LV P = 0.00009; 10×106 EPHA2: Day 0 IV vs LV P = 0.6, Day 30 IV vs LV P = 0.029.

Back to article page